Human toll-like receptor inhibitors and methods of use thereof

Inventors

Guiducci, Cristiana • Fearon, Karen L. • Barrat, Franck

Assignees

Dynavax Technologies Corp

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9868955-B2

Patent

Publication Date

2018-01-16

Expiration Date


Abstract

Provided herein are human Toll-like receptor (TLR)-inhibitors and methods for use in individuals having an autoimmune disease or an inflammatory disorder. The TLR inhibitors of the present disclosure are polynucleotides comprising an inhibitory motif for one or more of TLR7, TLR8 and TLR9.

Core Innovation

The disclosed immunoinhibitory polynucleotide consists of a nucleotide sequence arranged according to a specified formula of nucleotides or nucleotide analogs, wherein Nₓ comprises a 5′-terminal TTC trinucleotide and lacks a CG dinucleotide. The subject matter encompasses pharmaceutical compositions, conjugates, and delivery formats, including multivalent polymeric or proteinaceous spacers, liposomes, nanoparticles, and microcarriers. These compositions are administered in an amount effective to inhibit an immune response directed to TLR7, TLR8, and/or TLR9.

The disclosure reports immune-response and disease-model data demonstrating reduced TLR-mediated cytokine responses, including IL-6 inhibition, in human cellular and animal models without inhibiting several other specified signaling pathways. Experimental results further demonstrate decreased disease severity scores over time in cellular and animal models of arthritis and pancreatitis. The polynucleotides also reduce cytokine production induced by rheumatoid arthritis plasma, synovial fluid, and Sj–gren’s patient serum in monocytes.

Claims Coverage

The independent claims cover two inventive features directed to a structurally constrained polynucleotide and a method of administering a pharmaceutical composition containing the polynucleotide to inhibit an immune response.

Polynucleotide with a 5′-terminal TTC trinucleotide and no CG dinucleotide

Claim 1 recites a polynucleotide consisting of the nucleotide sequence of the specified formula, wherein each of N, X₁, X₂, X₃, and X₄ is a nucleotide or nucleotide analog, X₅X₆ is II, x is an integer from 0 to 50, Nₓ comprises a TTC trinucleotide located at the 5′ end of the polynucleotide, and the polynucleotide does not comprise a CG dinucleotide.

Method of inhibiting an immune response using a polynucleotide composition

Claim 4 recites a method comprising administering to an individual an amount of a pharmaceutical composition effective to inhibit an immune response, wherein the composition comprises a pharmaceutically acceptable excipient and the specified polynucleotide comprising a 5′-terminal TTC trinucleotide in the Nₓ region and no CG dinucleotide.

The independent claims cover the defined polynucleotide structure and its administration in a pharmaceutical composition to inhibit an immune response, with dependent claims further specifying sequence, length, linkage chemistry, TLR8-dependent responses, and target autoimmune or inflammatory disorders.

Stated Advantages

Inhibiting an immune response and reducing TLR-mediated cytokine responses, including IL-6 inhibition.

Inhibition of the immune response ameliorates one or more symptoms of an inflammatory disorder.

Reported disease-model data demonstrate reduced disease severity and disease scores over time in cellular and animal models following treatment.

Documented Applications

Inhibiting TLR-dependent immune responses, including TLR8-dependent immune responses, by administering a pharmaceutical composition comprising the polynucleotide.

Inhibiting immune responses associated with autoimmune or inflammatory disorders, including rheumatoid arthritis, pancreatitis, mixed tissue connective disease, systemic lupus erythematosus, antiphospholipid syndrome, irritable bowel disease, type I diabetes mellitus, and Sj–gren’s disease.

Addressing autoimmune disease associated with RNA-containing immune complexes.

Pharmaceutical compositions containing the polynucleotide and a pharmaceutically acceptable excipient for administration via various routes, delivery formats, and combination therapies.

Evaluation in experimental models of arthritis and pancreatitis, as well as inhibition of cytokine responses induced by rheumatoid arthritis plasma, synovial fluid, and Sj–gren’s patient serum in monocytes.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.